Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients. 

The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients. 

Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."

“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”

Sanofi will also cut the price of short-acting Apidra by 70 percent.

Share:
More In Business
Stretching Your Dollar: Caring for Your Pets This Holiday Season
With all of the stress surrounding the holiday season with gift-buying and planning family gatherings, it could be a chaotic time for all members of your family, including pets. Cesar Milan and Michael Ehrman, co-founders of Halo Collar, joined Cheddar News to provide tips on how to keep your pets stress-free for the upcoming holiday season.
United Airlines Introduces Self-Serve Snack Bar
United Airlines has introduced a new self-serve snack bar on its flights allowing economy passengers to help themselves to free snacks instead of relying on a flight attendant to get them.
Load More